Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Assets (2016 - 2025)

UroGen Pharma's Other Non-Current Assets history spans 10 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 776.23% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, up 776.23%, while the annual FY2025 figure was $5.2 million, 776.23% up from the prior year.
  • Other Non-Current Assets reached $5.2 million in Q4 2025 per URGN's latest filing, down from $6.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.8 million in Q3 2025 to a low of $66000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.9 million, with a median of $1.7 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: surged 3123.64% in 2021, then tumbled 81.95% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.3 million in 2021, then surged by 109.0% to $2.7 million in 2022, then fell by 25.62% to $2.0 million in 2023, then tumbled by 71.1% to $589000.0 in 2024, then surged by 776.23% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Other Non-Current Assets are $5.2 million (Q4 2025), $6.8 million (Q3 2025), and $801000.0 (Q2 2025).